Journal
Switching From Semaglutide to Tirzepatide: How It's Actually Done, and What It Costs
Released: Last reviewed:
The short answer
The switch is a restart, not a translation. No validated dose-equivalence chart exists between semaglutide and tirzepatide — they hit different receptor sets — so standard practice is: take the last semaglutide dose, begin tirzepatide at or near its 2.5-milligram starting dose on the next scheduled injection day (your prescriber sets the exact timing), and re-titrate on the label's four-week steps. The payoff case comes from the head-to-head: SURMOUNT-5 showed tirzepatide averaging 20.2 percent loss against semaglutide's 13.7 at maximum tolerated doses, which is why inadequate response or a true plateau on semaglutide is the classic trigger. The costs are two: a re-titration period where appetite control may feel lighter than your old maintenance dose, and a price move of roughly forty to two hundred seventy dollars a month upward, tier for tier.
Why restart instead of convert
Semaglutide is a GLP-1 agonist; tirzepatide adds GIP. Their milligrams aren't the same currency — 2.4 of one and 15 of the other aren't points on a shared scale — and tolerability to one doesn't guarantee tolerability to the other's equivalent intensity, which is exactly what titration schedules exist to discover safely. Prescribers therefore start tirzepatide low; some, weighing a patient's smooth semaglutide history, escalate on the faster edge of the label's allowances, but that's individualized judgment, not a chart. Expect the switch window to feel like a partial reset: the GI adjustment pattern from our side-effect timeline replays in miniature, and appetite suppression may dip below your old maintenance level for the first weeks — plan the transition for a low-stakes stretch of calendar, and don't read week-two hunger as the switch failing.
The washout question, and the money
Both drugs are once-weekly with long half-lives, and common practice is simple sequencing — last dose of one, first dose of the other at the next weekly slot — rather than a deliberate gap; your prescriber may adjust timing for side-effect history, and stacking doses of both is the one thing nobody does. On price: on the August 2026 record the move ran from semaglutide's one twenty-nine month-to-month (bmiMD) to tirzepatide's one sixty-nine (NexLife, now its standing price) or one seventy-nine (Henry, bmiMD) — a forty-to-fifty-dollar step (on October 15, 2026, Eden listed ninety-nine semaglutide and one twenty-nine tirzepatide a month flat); at the committed tiers, ninety-nine to one twenty-five-through-one thirty-nine. On brand, the jump is starker: a three forty-nine Wegovy pen or one forty-nine oral tablet to Zepbound's four forty-nine maintenance vials — and note the vial ladder gives switchers a break, since your first tirzepatide months at 2.5 and 5 milligrams price at two ninety-nine and three ninety-nine before the four forty-nine plateau. If you're switching within one telehealth program, confirm the new molecule's rate in writing before the first fill — the teaser mechanisms apply to switches too. And if insurance covers either drug, the twenty-five-dollar path outranks this entire arithmetic.
Questions people ask
What is the tirzepatide equivalent dose to semaglutide 2.4 mg?
There isn't one — no validated conversion exists between the molecules, because they act on different receptor sets. Standard practice restarts tirzepatide at or near 2.5 mg and re-titrates on the label's four-week steps, with prescriber judgment on pace. Any chart claiming milligram equivalence is invented.
Do I need a washout period between semaglutide and tirzepatide?
Common practice is simple sequencing — the new drug begins at the next scheduled weekly injection slot after the old one's last dose — rather than a deliberate gap, with prescriber adjustment for side-effect history. The firm rule is not overlapping doses of both.
How much more does tirzepatide cost after switching?
Roughly $40–$270 a month tier-for-tier: compounded floors move from $129 (semaglutide, bmiMD) to $169–$179; committed plans from $99 to $125–$139; brand from a $349 pen or $149 tablet to Zepbound's $449 maintenance vials — though the vial ladder starts switchers at $299/$399 during re-titration. Confirm the new rate in writing, and check insurance first.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.